Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

In recent trading, Syndax Pharmaceuticals Inc (SNDX) stock price has shown some volatility, fluctuating -27.42% over the last five trades and -20.41% over the past 30 trades. This represents a notable ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

On Thursday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $16.79 which represents a slight increase of $0.16 or 0.96% from the prior close of $16.63. The stock opened ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...